Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine

Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine

Summary: Bromocriptine is approved as a diabetes therapy, yet its therapeutic mechanisms remain unclear. Though bromocriptine’s actions have been mainly attributed to the stimulation of brain dopamine D2 receptors (D2R), bromocriptine also targets the pancreas. Here, we employ bromocriptine as a too...

Full description

Bibliographic Details
Main Authors: Despoina Aslanoglou, Suzanne Bertera, Laura Friggeri, Marta Sánchez-Soto, Jeongkyung Lee, Xiangning Xue, Ryan W. Logan, J. Robert Lane, Vijay K. Yechoor, Peter J. McCormick, Jens Meiler, R. Benjamin Free, David R. Sibley, Rita Bottino, Zachary Freyberg
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:iScience
Subjects:
Chemistry
biological sciences
molecular biology
Endocrinology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004222010434

Internet

http://www.sciencedirect.com/science/article/pii/S2589004222010434

Similar Items